UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED ~~JANUARY~~APRIL 3130, 2026

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Commission File Number: 001-14468

PURE Bioscience, Inc.

(Exact name of registrant as specified in its charter)

Delaware		33-0530289
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

771 Jamacha Rd., #512

El Cajon, California

92019

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (619) 596-8600

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.01 par value

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~March~~June 1615, 2026, there were ~~111~~130,~~886~~017,~~473~~569 shares of the registrant’s common stock, $0.01 par value per share, outstanding.

PURE Bioscience, Inc.

Form 10-Q

for the Quarterly Period Ended ~~January~~April 3130, 2026

Table of Contents

		~~Page~~	Page
PART I	~~FINANCIAL INFORMATION~~	FINANCIAL INFORMATION
Item 1.	~~Condensed Financial Statements~~	3Financial Statements	3
Item 2.	~~Management’s Discussion and Analysis of Financial Condition and Results of Operations~~	15Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	~~Quantitative and Qualitative Disclosures about Market Risk~~	22Quantitative and Qualitative Disclosures about Market Risk	22
Item 4.	~~Controls and Procedures~~	22Controls and Procedures	22
PART II	~~OTHER INFORMATION~~	OTHER INFORMATION
Item 1.	~~Legal Proceedings~~	23Legal Proceedings	23
Item 1A.	~~Risk Factors~~	23Risk Factors	23
Item 2.	~~Unregistered Sales of Equity Securities and Use of Proceeds~~	24Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	~~Defaults Upon Senior Securities~~	24Defaults Upon Senior Securities	24
Item 4.	~~Mine Safety Disclosures~~	24Mine Safety Disclosures	24
Item 5.	~~Other Information~~	24Other Information	24
Item 6.	~~Exhibits~~	25Exhibits	25
	~~Signatures~~	26Signatures	26

Part I - Financial Information

Item 1. Financial Statements

PURE Bioscience, Inc.

Condensed Consolidated Balance Sheets

	January 31, 2026			July 31, 2025
	April 30, 2026			July 31, 2025
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	~~198~~983,000		$	334,000
Accounts receivable		~~252~~242,000			474,000
Inventories, net		~~244~~232,000			141,000
Restricted cash		75,000			75,000
Prepaid expenses		1017,000			23,000
Total current assets		~~779~~1,549,000			1,047,000
Property, plant and equipment, net		9,000			11,000
Total assets	$	~~788~~1,558,000		$	1,058,000
Liabilities and stockholders’ deficiency
Current liabilities
Accounts payable	$	~~767~~719,000		$	784,000
Convertible notes payable to related parties, current		2,~~139~~754,000			—
Accrued liabilities		~~149~~181,000			154,000
Total current liabilities		3,~~055~~654,000			938,000
Convertible notes payable to related parties, non-current		43,~~006~~743,000			5,236,000
Total liabilities		7,~~061~~397,000			6,174,000
Commitments and contingencies		-			-
Stockholders’ deficiency					-
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding		—			—
Common stock, $0.01 par value: 200,000,000 shares authorized, 111,886,473 shares issued and outstanding at January 31, 2026, and July 31, 2025		1,119,000			1,119,000
Common stock, $0.01 par value: 200,000,000 shares authorized, 130,017,569 shares issued and outstanding at April 30, 2026, and 111,886,473 at July 31, 2025		1,301,000			1,119,000
Additional paid-in capital		~~132~~133,~~851~~727,000			132,759,000
Accumulated deficit		(140,~~243~~867,000	)		(138,994,000	)
Total stockholders’ deficiency		(65,~~273~~839,000	)		(5,116,000	)
Total liabilities and stockholders’ deficiency	$	~~788~~1,558,000		$	1,058,000

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	2026			2025			2026			2025
	Six Months Ended						Three months Ended
	Nine Months Ended						Three months Ended
	January 31,						January 31,
	April 30,						April 30,
	2026			2025			2026			2025
Net product sales	$	1,~~150~~656,000		$	~~946~~1,435,000		$	~~443~~506,000		$	~~391~~489,000
Royalty revenue		2,000			13,000			~~1,000~~-			—2,000
Total revenue		1,~~152~~658,000			~~947~~1,438,000			~~444~~506,000			~~391~~491,000
Cost of goods sold		~~464~~701,000			~~395~~603,000			~~206~~237,000			~~164~~208,000
Gross profit		~~688~~957,000			~~552~~835,000			~~238~~269,000			~~227~~283,000
Operating costs and expenses
Selling, general and administrative		12,~~590~~298,000			12,~~752~~528,000			~~847~~708,000			~~871~~776,000
Research and development		~~160~~239,000			~~152~~243,000			7479,000			8191,000
Total operating costs and expenses		12,~~750~~537,000			12,~~904~~771,000			~~921~~787,000			~~952~~867,000
Loss from operations		(1,~~062~~580,000	)		(1,~~352~~936,000	)		(~~683~~518,000	)		(~~725~~584,000	)
Other income (expense)
Other income (expense), net		8,000			(379,000	)		~~(1,000~~-	)		(382,000	)
Interest expense, net		(~~195~~301,000	)		(~~132~~210,000	)		(~~101~~106,000	)		(7078,000	)
Total other income (expense)		(~~187~~293,000	)		(~~135~~131,000	)		(~~102~~106,000	)		~~(73~~4,000	)
Net loss	$	(1,~~249~~873,000	)	$	(12,~~487~~067,000	)	$	(~~785~~624,000	)	$	(~~798~~580,000	)
Basic and diluted net loss per share	$	(0.0102	)	$	(0.0102	)	$	(0.01	)	$	(0.01	)
Shares used in computing basic and diluted net loss per share		111,~~886~~543,~~473~~047			111,856,473			~~111~~110,~~886~~833,~~473~~042			111,856,473

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statement of Stockholders’ Deficiency

(Unaudited)

	Shares		Amount		Capital		Deficit			~~Equity~~Deficiency			Shares		Amount		Capital		Deficit			~~Equity~~Deficiency
	Six Months Ended January 31, 2026												Six Months Ended January 31, 2025
	Nine Months Ended April 30, 2026												Nine Months Ended April 30, 2025
	Common Stock				Additional Paid-In		Accumulated			Total Stockholders’			Common Stock				Additional Paid-In		Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Deficiency			Shares		Amount		Capital		Deficit			Deficiency
Balances at beginning of period		111,886,473	$	1,119,000	$	132,759,000	$	(138,994,000	)	$	(5,116,000	)		111,856,473	$	1,119,000	$	132,612,000	$	(136,595,000	)	$	(2,864,000	)
Share-based compensation expense - stock options		—		—		92147,000		—			92147,000			—		—		84114,000		—			84114,000
Net loss		—		—		—		(1,249,000	)		(1,249,000	)		—		—		—		(1,487,000	)		(1,487,000	)
Share-based compensation expense - restricted stock units		—		—		—		—			—			—		—		3,000		—			3,000
Balances at end of period (Unaudited)		111,886,473	$	1,119,000	$	132,851,000	$	(140,243,000	)	$	(6,273,000	)		111,856,473	$	1,119,000	$	132,696,000	$	(138,082,000	)	$	(4,267,000	)
Issuance of common stock in private placement, net		18,131,096		182,000		821,000					1,003,000			—		—		—		—			—
Net loss		—		—		—		(1,873,000	)		(1,873,000	)		—		—		—		(2,067,000	)		(2,067,000	)
Balances at end of period (Unaudited)		130,017,569	$	1,301,000	$	133,727,000	$	(140,867,000	)	$	(5,839,000	)		111,856,473	$	1,119,000	$	132,729,000	$	(138,662,000	)	$	(4,814,000	)

	Shares		Amount		Capital		Deficit			~~Equity~~Deficiency			Shares		Amount		Capital		Deficit			~~Equity~~Deficiency
	Three Months Ended January 31, 2026												Three Months Ended January 31, 2025
	Three Months Ended April 30, 2026												Three Months Ended April 30, 2025
	Common Stock				Additional Paid-In		Accumulated			Total Stockholders’			Common Stock				Additional Paid-In		Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Deficiency			Shares		Amount		Capital		Deficit			Deficiency
Balances at beginning of period (Unaudited)		111,886,473	$	1,119,000	$	132,~~793~~851,000	$	(~~139~~140,~~458~~243,000	)	$	(56,~~546~~273,000	)		111,856,473	$	1,119,000	$	132,~~669~~696,000	$	(~~137~~138,~~284~~082,000	)	$	(34,~~496~~267,000	)
Share-based compensation expense - stock options		—		—		5855,000		—			5855,000			—		—		2730,000		—			2730,000
Net loss		—		—		—		(785,000	)		(785,000	)		—		—		—		(798,000	)		(798,000	)
Share-based compensation expense - restricted stock units		—		—		—		—			—			—		—		3,000		—			3,000
Balances at end of period (Unaudited)		111,886,473	$	1,119,000	$	132,851,000	$	(140,243,000	)	$	(6,273,000	)		111,856,473	$	1,119,000	$	132,696,000	$	(138,082,000	)	$	(4,267,000	)
Issuance of common stock in private placement, net		18,131,096		182,000		821,000		—			1,003,000			—		—		—		—			—
Net loss		—		—		—		(624,000	)		(624,000	)		—		—		—		(580,000	)		(580,000	)
Balances at end of period (Unaudited)		130,017,569	$	1,301,000	$	133,727,000	$	(140,867,000	)	$	(5,839,000	)		111,856,473	$	1,119,000	$	132,729,000	$	(138,662,000	)	$	(4,814,000	)

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	2026			2025
	Six Months Ended
	Nine Months Ended
	January 31,
	April 30,
	2026			2025
Operating activities
Net loss	$	(1,~~249~~873,000	)	$	(12,~~487~~067,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		92147,000			84117,000
Depreciation and amortization		2,000			1,000
Depreciation		2,000			2,000
Changes in operating assets and liabilities:
Accounts receivable		~~222~~232,000			~~118~~11,000
Inventories		(~~103~~91,000	)		(1975,000	)
Prepaid expenses		136,000			(314,000	)
Interest on note payable to related parties		189,000			126,000
Interest on note payable		291,000			200,000
Accounts payable and accrued liabilities		(2238,000	)		~~133~~239,000
Net cash used in operating activities		(~~856~~1,324,000	)		(1,~~047~~559,000	)
Financing activities
Net proceeds from note payable to related parties		720,000			900,000
Net proceeds from private placement		1,003,000			—
Net cash provided by financing activities		720,000			900,000
Net proceeds from note payable to related parties		970,000			1,750,000
Net decrease in cash, cash equivalents, and restricted cash		(136,000	)		(147,000	)
Net cash provided by financing activities		1,973,000			1,750,000
Net increase in cash, cash equivalents, and restricted cash		649,000			191,000
Cash, cash equivalents, and restricted cash at beginning of period		409,000			424,000
Cash, cash equivalents, and restricted cash at end of period	$	~~273~~1,058,000		$	~~277~~615,000
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	~~198~~983,000		$	~~202~~540,000
Restricted cash	$	75,000		$	75,000
Total cash, cash equivalents and restricted cash	$	~~273~~1,058,000		$	~~277~~615,000
Supplemental disclosure of cash flow information
Cash paid for taxes	$	4,000			—

See accompanying notes.

PURE Bioscience, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

For the three and ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us,” “its” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary, ETI H20 Inc.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and ~~six~~nine months ended ~~January~~April 3130, 2026 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2026. The July 31, 2025 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2025 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 29, 2025.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

2. Liquidity and Going Concern

The Company has a history of recurring losses, and as of ~~January~~April 3130, 2026 it has a stockholders deficiency of $65,~~273~~839,000. During the ~~six months~~nine months ended ~~January~~April 3130, 2026, it recorded a net loss of $1,~~249~~873,000 on recorded net revenue of $1,~~152~~658,000. In addition, during the ~~six months~~nine months ended ~~January~~April 3130, 2026 the Company used $~~856~~1,324,000 in operating activities resulting in a cash balance of $~~198~~983,000 as of ~~January 31~~April 30, 2026. The Company’s history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding its ability to continue as a going concern. The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended July 31, 2025, has also expressed substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern.

The Company’s future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, its products; the Company’s success and the success of its partners in selling our products; the Company’s success and the success of its partners in obtaining regulatory approvals to sell its products; the costs of further developing the Company’s existing products and technologies; the extent to which the Company invests in new product and technology development; and the costs associated with the continued operation, and any future growth, of its business. The outcome of these and other forward-looking factors will substantially affect its liquidity and capital resources.

Until the Company can continually generate positive cash flow from operations, it will need to continue to fund its operations with the proceeds of offerings of our equity and debt securities. However, the Company cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or to its stockholders. If the Company raises additional funds from the issuance of equity securities, substantial dilution to its existing stockholders would likely result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business.

3. Significant Accounting Policies

Revenue Recognition

The Company recognizes revenue in accordance with the Financial Accounting Standards Board or the FASB, Accounting Standards Codification or ASC, Topic 606, Revenue from Contracts with Customers or Topic 606. Under Topic 606, revenue is recognized at an amount that reflects the consideration to which it expects to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

Under Topic 606, the Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services.

The Company’s technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers residual protection and formulates well with other compounds. The Company sells various configurations and dilutions of SDC direct to customers and through distributors. The Company currently offers PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. The Company also offers PURE Control^® as a direct food contact processing aid.

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which it considers to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating the standalone selling price.

Product sales generally consist of a single performance obligation that it satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) it has transferred physical possession of the products, (b) it has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

The Company’s direct customer and distributor sales are invoiced based on received purchase orders. Its payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after it satisfies its performance obligation. The majority of our customers are on 30 day payment terms. The Company currently offers no right of return on invoiced sales and maintain no allowance for sales returns.

Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.

The Company does not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

A summary of ~~our~~the Company’s revenue by product type for the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025 is as follows:

Summary of Revenue by Product

	2026		2025
	January 31,
	April 30,
	2026		2025
PURE Hard Surface	$	1,~~136~~550,000	$	~~774~~1,242,000
SILVÉRION		14106,000		~~172~~193,000
Revenue	$	1,~~150~~656,000	$	~~946~~1,435,000

8A summary of the Company’s revenue by product type for the three months ended April 30, 2026 and 2025 is as follows:

A summary of our revenue by product type for the three months ended January 31, 2026 and 2025 is as follows:

	2026		2025
	April 30,
	2026		2025
PURE Hard Surface	$	92,000	$	468,000
SILVÉRION		414,000		21,000
Revenue	$	506,000	$	489,000

	2026		2025
	January 31,
	2026		2025
PURE Hard Surface	$	429,000	$	384,000
SILVÉRION		14,000		7,000
Revenue	$	443,000	$	391,000

Variable Consideration

The Company records revenue from customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. From time to time, the Company ~~offer~~offers sales promotions on its products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Net Loss Per Share

Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. The Company’s diluted net loss per common share is the same as its basic net loss per common share because itthe ~~incurred~~Company incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, ~~restricted~~ restricted stock units, and warrants would have an anti-dilutive effect. As of ~~January~~April 3130, 2026 and 2025, stock options, shares issuable ~~upon~~ upon the conversion of debt, and shares issuable under restricted stock unit awards of 6871,~~640~~870,~~988~~672 and 4250,~~075~~255,~~936~~145, respectively, have ~~been~~ been excluded from the computation of diluted shares outstanding.

	2026		2025
	January 31,
	April 30,
	2026		2025
Common stock options		13,395,000		910,~~895~~060,000
Restricted stock units		712,500		~~712~~742,500
Shares issuable upon the conversion of debt		5457,~~533~~763,~~488~~172		3139,~~468~~452,~~436~~645
Total		6871,~~640~~870,~~988~~672		4250,~~075~~255,~~936~~145

Accounts Receivable

Trade accounts receivable are recorded net of allowances for doubtful accounts. The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company become aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of past due trade accounts receivable outstanding. Management determined no allowance for doubtful accounts was necessary at January 31, 2026 and July 31, 2025.

Inventory

Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Inventories consist of the following:

Schedule of Inventories

	January 31, 2026		July 31, 2025
	April 30, 2026		July 31, 2025
Raw materials	$	1612,000	$	14,000
Finished goods		~~228~~220,000		127,000
Inventories	$	~~244~~232,000	$	141,000

~~Inventories~~Property, atPlant ~~January 31, 2026~~ and ~~July 31, 2025, are net of reserve for inventory obsolescence of $147,000 and $212,000, respectively.~~Equipment

Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value. There were no impairments during the nine months ended April 30, 2026.

Share-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services. It accounts for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period.

The Company estimates the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures.

Concentrations

Gross product sales. For the three ~~months~~and ~~ended~~nine ~~January 31, 2026, no customers accounted for 10% of net product sales. For the six~~ months ended ~~January~~April 3130, 2026, one customer accounted for 3015% and 21% of net product sales., respectively. For the ~~three~~nine months ended ~~January~~April 3130, 2025, ~~one~~two ~~customer~~ customers accounted for 1213% and 10% of net product sales. For the ~~six~~three months ended ~~January 31~~April 30, 2025, ~~two~~no customers accounted for ~~18%~~greater ~~and~~than 1110% of net product ~~sales,~~ ~~respectively~~sales.

Accounts receivable. As of ~~January~~April 3130, 2026, the Company had accounts receivable from ~~three~~one ~~customers~~customer that comprised of 1014% of total accounts ~~receivable,~~ ~~respectively~~receivable. As of ~~January~~July 31, 2025, the Company had accounts receivable from ~~one~~two ~~customer~~customers that comprised 40% and 12% of total accounts receivable.

Purchases. For the three months ended January 31, 2026, two vendors accounted for 20% and 16% of purchases. For the six months ended January 31, 2026, two vendors accounted for 28% and 15% of purchases. For the three months ended January 31, 2025, one vendor accounted for 22% of purchases. For the six months ended January 31, 2025, one vendor accounted for 28% of purchases.

Accounts payable. As of January 31, 2026, the Company’s largest vendor accounted for 8.3% of the total accounts payable. As of January 31, 2025, the Company’s largest vendor accounted for 10% of the total trade accounts payable.

Purchases. For the three months ended April 30, 2026, one vendor accounted for 33% of the Company’s purchases. For the nine months ended April 30, 2026, two vendors accounted for 29% and 13% of the Company’s purchases.

For the three months ended April 30, 2025, three vendors accounted for 30%, 11% and 10% of the Company’s purchases, respectively. For the nine months ended April 30, 2025, two vendors accounted for 26% and 10% of the Company’s purchases, respectively.

Accounts payable. As of April 30, 2026, the Company’s largest vendor accounted for 12% of the total accounts payable. As of July 31, 2025, one vendor accounted for 13% of the total trade accounts payable.

Segments

The Company operates in one segment for the manufacture and distribution of its products. In accordance with the “Segment Reporting” Topic of the ASC, its Chief Operating Decision Maker (“CODM”) has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. The following table presents significant segment expenses and other segment items regularly reviewed by our CODM:

For the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025.

	2026			2025
	For the Six Months Ended January 31,
	For the Nine Months Ended April 30,
	2026			2025
Revenue	$	1,~~152~~658,000		$	~~947~~1,438,000
Less:
Cost of goods sold		(~~464~~701,000	)		(~~395~~603,000	)
General and administrative		(12,~~498~~151,000	)		(12,~~668~~411,000	)
Research and development		(~~160~~239,000	)		(~~152~~243,000	)
Stock-based compensation		(92147,000	)		(84117,000	)
Interest expense, net		(~~195~~301,000	)		(~~132~~210,000	)
Other income (expense)		8,000			(3,000	)
Other income		8,000			79,000
NET LOSS	$	(1,~~249~~873,000	)	$	(12,~~487~~067,000	)

For the three months ended ~~January~~April 3130, 2026 and 2025.

	2026			2025
	For the Three Months Ended January 31,
	For the Three Months Ended April 30,
	2026			2025
Revenue	$	~~444~~506,000		$	~~391~~491,000
Less:
Cost of goods sold		(~~206~~237,000	)		(~~164~~208,000	)
General and administrative		(~~789~~653,000	)		(~~844~~743,000	)
Research and development		(7479,000	)		(8191,000	)
Stock-based compensation		(5855,000	)		(2733,000	)
Interest expense, net		(~~101~~106,000	)		(7078,000	)
Other income (expense)		(1,000	)		(3,000	)
Other income		-			82,000
NET LOSS	$	(~~785~~624,000	)	$	(~~798~~580,000	)

4. Recent Accounting Pronouncements

In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on its financial statement disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

5. Convertible Notes Payable to Related Parties

Schedule of Convertible Notes

	Maturity		Interest Rate		~~Interest Rate~~		April 30, 2026		~~January 31, 2026~~		July 31, 2025		~~July 31, 2025~~
Fiscal 2023 Notes (a)	June 2026	~~June 2026~~		7.55	%	~~7.55~~	%$	1,015,000	$	~~1,015,000~~	$	1,015,000	$	~~1,015,000~~
Fiscal 2024 Notes (b)		October 2026 to June 2027				7.81	%			1,785,000				1,785,000
Fiscal 2023 Notes (a)	June 2026			7.55	%		$	1,015,000			$	1,015,000
Fiscal 2025 Notes (c)		September 2027 to July 2028				6.79%- 7.88	%			2,000,000				2,000,000
Fiscal 2024 Notes (b)	October 2026 to June 2027			7.81	%			1,785,000				1,785,000
Fiscal 2026 Notes (d)		October to December 2028				6.34% - 6.68	%			720,000				—
Fiscal 2025 Notes (c)	September 2027 to July 2028			6.79%- 7.88	%			2,000,000				2,000,000
										5,520,000				4,800,000
Fiscal 2026 Notes (d)	October to February 2029			6.16% - 6.68	%			970,000				—
Accrued interest										625,000				436,000
								5,770,000				4,800,000
Total									$	6,145,000			$	5,236,000
Accrued interest								727,000				436,000
Total							$	6,497,000			$	5,236,000

(a) In fiscal 2023, the Company entered into a Note Purchase Agreement (the “2023 Note Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes with an aggregate principal balance of $1,015,000 (the “2023 Private Placement”). Messrs. Tom Y. Lee and Ivan Chen, each a member of the Company’s Board invested $1,000,000 and $15,000, respectively in the 2023 Private Placement, through affiliates or directly. As of ~~January~~April 3130, 2026, $1,015,000 of principal was outstanding under the 2023 Private Placement, which amount is currently due. (b) In fiscal 2024, the Company entered into a Note Purchase Agreement (the “2024 Note Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes with an aggregate principal balance of $1,785,000 (the “2024 Private Placement”). Tom Y. Lee invested $1,785,000 in the 2024 Private Placement, through affiliates or directly. As of ~~January~~April 3130, 2026, $1,785,000 of principal was outstanding under the 2024 Private Placement, of which $~~785~~1,285,000 is currently due. (c) In fiscal 2025, the Company entered into a Note Purchase Agreement (the “2025 Note Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes with an aggregate principal balance of $2,000,000 (the “2025 Private Placement”). Tom Y. Lee invested $2,000,000 in the 2025 Private Placement, through affiliates or directly. As of ~~January~~April 3130, 2026, $2,000,000 of principal was outstanding under the 2025 Private Placement. (d) During the period ended ~~January~~April 3130, 2026, the Company entered into a Note Purchase Agreement (the “2026 Note Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the 2026 Note Purchase Agreement, the “Note Documents”) with an aggregate principal balance of $~~720~~970,000 (the “2026 Private Placement”).The Note Documents provide for subsequent closings for an aggregate offering size of $2.0 million in principal balance. Tom Y. Lee, invested $~~720~~970,000 in the 2026 Private Placement, through affiliates or directly. The disinterested members of the Board approved the 2026 Private Placement. As of ~~January~~April 3130, 2026, $~~720~~970,000 of principal was outstanding under the 2026 Private Placement.

The Notes are unsecured, and provide that the interest rate to the Lenders shall accrue at rates between 6.3416% - 7.88% compounded annually. The Maturity Date (as defined in the Notes) of the Notes is the third-year anniversary of the date of issuance, or such earlier date as the Notes provide.

Conversion. All or any portion of the principal amount of the Notes, plus accrued and unpaid interest, is convertible at any time, in whole or in part, at a Lender’s or the Company’s option, into shares of the Company’s common stock at a conversion price equal to the 30-day volume-weighted average price of the Company’s common stock as reported on the market or exchange on which the Company’s common stock is listed or quoted for trading (the “VWAP”) on the date of conversion on the last trading day prior to the date of conversion, provided that such conversion price is:

● at least $0.15 per share and less than or equal to $0.23 per share for the fiscal 2023 Notes and the $785,000 October 2023 Note ● at least $0.13 per share and less than or equal to $0.21 per share for the $500,000 March 2024 Note ● at least $0.115 per share and less than or equal to $0.195 per share for the $500,000 June 2024 Note ● at least $0.095 per share and less than or equal to $0.175 per share for the $1,750,000 September 2024 to April 2025 Notes ● at least $0.10 per share and less than or equal to $0.18 per share for the $250,000 July 2025 Notes and $350,000 for the October 2025 Note ● at least $0.08 per share and less than or equal to $0.16 per share for the $70,000 December 2025 Note ● at least $0.07 per share and less than or equal to $0.15 per share for the $300,000 December 2025 Note ● at least $0.08 per share and less than or equal to $0.16 per share for the $250,000 February 2026 Note

Additionally, at any time following the first year anniversary of the Notes, the holders of a majority of the outstanding principal balance under ~~the~~ the Notes may elect specified in writing to convert all of the Notes at a conversion price equal to the VWAP, provided that the ~~conversion~~ conversion price is equal to at least $0.08, $0.07, $0.08, $0.10, $0.095, $0.115, $0.13 and $0.15 per share, as discussed above, subject to certain customary adjustments.

As of ~~January~~April 3130, 2026, none of the Notes have been repaid in cash or converted into Common Stock.

Other terms of the Note Agreements.

Further, on all the notes discussed above, in the event of certain corporate transactions, all outstanding principal and unpaid accrued interest due on such Notes shall be automatically converted into conversion shares on the trading day immediately prior to the closing date of such corporate transaction. The number of shares to be issued upon such conversion shall be based on the VWAP on the last trading day prior to the public announcement of the execution of the definitive documents with respect to such transaction.

Events of Default. The Notes Documents provide for certain events of default that are typical for a transaction of this type, including, among other things, default in the payment of principal or interest for more than 30 days, the Company’s making an assignment for the benefit of creditors, within 15 days after the commencement of bankruptcy proceedings against the Company, or breach of certain covenants described below.

Covenants. The Company will be subject to certain customary covenants regarding the current public information, reservation of adequate share reserve, and maintenance of intellectual property rights, among other customary matters. As of ~~January~~April 3130, 2026, the Company was in compliance of all covenants.

During the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025, the Company recognized $~~190~~291,000 and $~~126~~200,000 of interest expense related to the 2026, 2025, 2024 and 2023 Notes, respectively. As of ~~January~~April 3130, 2026, interest of $~~625~~727,000 was added to the principal resulting in a balance owed of $6,~~145~~497,000. In addition, as of ~~January~~April 3130, 2026, the Notes and accrued interest were convertible into 5457,~~533~~763,~~488~~172 shares of common stock.

6. ~~Stockholders’~~Private ~~Equity~~Placement Financing

On April 30, 2026, the Company completed a closing (the “Closing”) of a private placement financing (the “Private Placement Financing”) to accredited investors (the “Investors”). The Company raised $1.0 million in the Closing and issued an aggregate of 18,131,096 shares (collectively, the “Shares”) of the Company’s common stock at a purchase price of $0.0553 per share. The Shares issued in the Private Placement Financing were issued pursuant to a securities purchase agreement entered into with the Investors. Mr. Tom Y. Lee, a member of the Company’s Board of Directors (the “Board”), invested approximately $700,000 directly and through his affiliates. In addition, Ivan Chen, a member of the Board, invested $27,650. The disinterested members of the Board approved the Private Placement Financing.

The net proceeds to the Company from the Closing, after deducting fees and other offering expenses, were approximately $1.0 million. The Company expects to use the net proceeds for general corporate purposes, including the Company’s research and development efforts, and for general administrative expenses and working capital.

7. Stockholders’ Equity

Restricted Stock Units

The Company issues restricted stock unit awards, or RSUs, to key management and as compensation for services to consultants and others. ~~The~~ The RSUs typically vest over a ~~one1~~one 1 to ~~three3~~three 3-year period and carry a ~~ten10~~ten 10-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortize those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term. As of ~~January~~April 3130, 2026, all the RSUs had vested and 712,500 RSUs are issuable as of ~~January~~April 3130, 2026.

During the nine months ended April 30, 2025, the Company granted 30,000 RSU’s to a third-party consultant for manufacturing services. The RSU’s vested 100% on the date of grant. As a result, the Company recognized the entire fair value of $3,000 of compensation cost relating to the vesting of the RSUs.

Stock Option Plans

2024 Equity Incentive Plan

The Company’s shareholders approved its 2024 Equity Incentive Plan, or the 2024 Plan, in February 2024, which has a share reserve of of 10,000,000 shares of common stock that were registered under a Form S-8 filed with the SEC in August 2024. The 2024 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to its employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board. The 2024 Plan replaced the prior amended and restated 2007 and 2017 shareholder approved equity plans. As of April ~~January 31~~30, 2026, there were 4,~~105~~165,000 shares available for issuance under the 2024 Plan.

During the six months ended January 31, 2026, the Compensation Committee of the Board of Directors granted 3,395,000 stock options to the Company’s employees, officers, directors and consultants with a fair value of $218,000 as determined by the Black Scholes option pricing model. The vesting terms of the options vary between one and two years and carry a ten-year term.13

During the nine months ended April 30, 2026, the Compensation Committee of the Board of Directors granted 3,395,000 stock options to the Company’s employees, officers, directors and consultants with a fair value of $218,000 as determined by the Black Scholes option pricing model. The vesting terms of the options vary between one and two years and carry a ten-year term.

A summary of our stock option activity is as follows:

Schedule of Stock Option Activity

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2025		10,060,000			0.32	$	—
Granted		3,395,000			0.07		—
Exercised		—			—		—
Cancelled		(60,000	)		1.30		—
Outstanding at January 31, 2026		13,395,000			0.26	$	—
Outstanding at April 30, 2026		13,395,000			0.26	$	—

The weighted-average remaining contractual term of options outstanding at ~~January~~April 3130, ~~2026~~2025 was 76.0685 years.

At ~~January~~April 3130, 2026, options to purchase 11,~~095~~697,~~000~~500 shares of common stock were exercisable. These options had a weighted-average exercise price of $0.2928 and a weighted average remaining contractual term of 6.5648 years. The total unrecognized compensation cost related to unvested stock option grants as of ~~January~~April 3130, 2026 was approximately $~~146~~97,000 and the weighted average period over which these grants are expected to vest is 0.7550 years.

For the ~~six~~nine months ended ~~January~~April 3130, 2026, share-based compensation expense for stock options that vested during the period was $92147,000. For the ~~six~~nine months ended ~~January~~April 3130, 2025, share-based compensation expense for stock options that vested during the period was $84114,000.

13The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

Schedule of Fair Value Assumptions

	For the six months ended January 31,
	For the nine months ended April 30,
	2026			2025
Volatility		145.17	%		118.49	%
Risk-free interest rate		4.12	%		34.8617	%
Dividend yield		—	%		—	%
Expected life		5.34			5.2625

Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

WeThe ~~have~~Company has never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

78. Related Party Transactions

As of ~~January~~April 3130, 2026 and ~~January~~April 3130, 2025, accounts payable include $~~231~~235,000 and $~~228~~249,000, respectively, in board fees due to officers and ~~directors,~~ ~~respectively~~directors.

89. Subsequent Events

~~Subsequent~~The toCompany’s ~~January~~stockholders ~~31,~~approved ~~2026,~~an amendment to the Company’s ~~issued~~Certificate ~~additional~~of ~~2026~~Incorporation ~~Notes~~ to ~~Mr.~~increase ~~Lee pursuant to~~ the ~~2026~~number ~~Note~~of ~~Purchase~~authorized ~~Agreement in a subsequent~~shares ~~closing~~of ~~with~~common anstock ~~aggregate~~from ~~principal~~200,000,000 ofshares $to 250,000,000 shares. The ~~conversion~~amendment ~~and~~became ~~terms~~effective ofupon ~~the~~filing ~~Notes~~with ~~are practically identical to~~ the ~~Notes~~Secretary ~~issued~~of State ~~during~~of the ~~six~~State ~~months~~of ~~ended~~Delaware ~~January~~on 31May 27, 2026.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

All references in this Item 2 and elsewhere in this Quarterly Report to “PURE,” “we”, “our,” “us” and the “Company” refer to PURE Bioscience, Inc., a Delaware corporation, and our wholly owned subsidiary, ETI H2O, Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements contained elsewhere in this Quarterly Report.

The discussion in this section contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “would” or “will” or the negative of these terms or other comparable terminology, but their absence does not mean that a statement is not forward-looking. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which could cause our actual results to differ from those projected in any forward-looking statements we make. Several risks and uncertainties we face are discussed in more detail under “Risk Factors” in Part II, Item 1A of this Quarterly Report or in the discussion and analysis below. You should, however, understand that it is not possible to predict or identify all risks and uncertainties and you should not consider the risks and uncertainties identified by us to be a complete set of all potential risks or uncertainties that could materially affect us. You should not place undue reliance on the forward-looking statements we make herein because some or all of them may turn out to be wrong. We undertake no obligation to update any of the forward-looking statements contained herein to reflect future events and developments, except as required by law. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes to those financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC. This broad-spectrum, non-toxic antimicrobial agent is available in liquid form and various concentrations, distinguished by its superior efficacy, reduced toxicity, non-causticity, and the inability of bacteria to develop resistance.

Our SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency, or EPA, the United States Food and Drug Administration, or FDA, and Health Canada. In addition to manufacturing and distributing these products, we also supply SDC-based formulations as raw material ingredients for personal care products.

We see significant market opportunities for our safe and effective SDC-based solutions, particularly in the food industry. Our registered offerings include PURE® Hard Surface, a food contact surface sanitizer and disinfectant designed for restaurant chains, food processors, and transportation companies, as well as PURE Control®, a direct food contact processing aid. Our products are sold directly to end-use customers, as well as third-party distributors who market and sell our products across various industries, maximizing our reach and impact.

Business Strategy

Our goal is to establish a sustainable company by commercializing SDC-based products developed through our proprietary technology platform. We aim to deliver leading antimicrobial solutions that tackle food safety risks across the entire food industry supply chain. Our products are sold directly to end-use customers and through our expanding distribution network. Key elements of our business strategy include:

Growing and supporting our distribution network. Expanding sales through distribution provides the following:

	a.	Expanded Reach: Distributors often have established networks and customer relationships, allowing us to access new markets and customer segments more efficiently.
	b.	Cost Savings: Utilizing distributors can reduce overhead costs associated with logistics, warehousing, and inventory management.
	c.	Market Knowledge: Distributors typically have local market insights and expertise, helping us navigate regional preferences and regulatory requirements.
	d.	Faster Time to Market: Distributors can accelerate product availability in geographic regions throughout the country, enabling quicker responses and shortening the sales cycle.
	e.	Sales Support: Distributors provide additional sales resources and support, such as training and promotional activities, enhancing product visibility.
	f.	Scalability: Distributors can easily scale operations to accommodate growth without requiring significant investment from the manufacturer.
	g.	Customer Service: Local distributors can offer better customer support, including faster response times and tailored services to meet specific client needs.

	2.	Continuing to partner with third parties seeking, or intending to seek, approvals to market SDC-based products outside the U.S.
	3.	Developing additional proprietary products and applications.
	4.	Protecting and enhancing our intellectual property.

In addition to our existing food safety products, we plan to leverage our technology platform through licensing and distribution collaborations to create new products and explore additional markets, aiming to generate multiple revenue streams.

Financial Overview

This financial overview provides a general description of our revenue and expenses.

Net Product Sales

We contract manufacture and sell SDC-based products for end use, and as a raw material for manufacturing use. We recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Any amounts received prior to satisfying revenue recognition criteria are recorded as deferred revenue. See “Critical Accounting Policies and Estimates – Revenue Recognition”.

Cost of Goods Sold

Cost of goods sold for product sales includes direct and indirect costs to manufacture products, including materials consumed, manufacturing overhead, shipping costs, salaries, benefits, reserved inventory, and related expenses of operations. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Selling, General and Administrative

Selling, general and administrative expense consists primarily of salaries and other related costs for personnel in business development, sales, finance, accounting, information technology, and executive functions. Other selling, general and administrative costs include product marketing, advertising, and trade show costs, as well as public relations and investor relations, facility costs, and legal, accounting and other professional fees.

Research and Development

Our research and development activities are focused on leveraging our technology platform to develop additional proprietary products and applications. Research and development expense consists primarily of personnel and related costs, product registration expenses, and third-party testing. We expense research and development costs as incurred.

Other Income (Expense)

We record interest income, interest expense, as well as other non-operating transactions, as other income (expense) in our consolidated statements of operations.

Results of Operations

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our results of operations will be affected for the foreseeable future by several factors that may contribute to these periodic fluctuations, including fluctuations in the buying patterns of our current or potential customers for which we have no visibility, the mix of product sales including a change in the percentage of higher or lower margin formulations and packaging configurations of our products, the cost of product sales including component costs, our inability for any reason to be able to meet demand, the achievement and timing of research and development and regulatory milestones, unforeseen changes in expenses, including non-cash expenses such as the fair value of equity awards granted and the fair value change of derivative liabilities, the calculation of which includes several variable assumptions, and unforeseen manufacturing or supply issues, among other issues. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance. As of the date of this filing, we are not aware of any trends in these factors or events or conditions that we believe are reasonably likely to impact our results of operations in the future.

Comparison of the Three Months Ended ~~January~~April 3130, 2026 and 2025

Net Product Sales

Net product sales were $~~443~~506,000 and $~~391~~489,000 for the three months ended ~~January~~April 3130, 2026 and 2025, respectively. The increase of $5217,000 ~~was~~ was attributable to increased sales across our ~~end-user~~distribution network. Our top customer accounted for $3378,000 of net product sales for the three months ended ~~January~~April 3130, 2026.

For the three months ended ~~January~~April 3130, 2026, noone customer accounted for 15% of net product sales. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

For the three months ended ~~January~~April 3130, 2025, ~~one~~no ~~customer accounted for 12% of net product sales, respectively. No other~~ individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

Cost of Goods Sold

Cost of goods sold was $~~206~~237,000 and $~~164~~208,000 for the three months ended ~~January~~April 3130, 2026 and 2025, respectively. The increase of $4229,000 was primarily attributable to increased sales during the current quarter.

Gross margin as a percentage of net product sales, ~~or gross margin percentage,~~ was 53% and 5857% for the three months ended ~~January~~April 3130, 2026 and 2025, respectively. The decrease in gross margin percentage was primarily attributable to increased sales of ~~higher~~lower margin packaging configurations of our products during the current quarter ended ~~January~~April 3130, ~~2025, as compared with the current period~~2026.

Selling, General and Administrative Expense

Selling, general and administrative expense was $~~847~~708,000 and $~~871~~776,000 for the three months ended ~~January~~April 3130, 2026 and 2025, respectively. The decrease of $68,000 was ~~primarily~~due ~~attributable~~ to ~~decreased~~reduced board ~~fees,~~of ~~personnel~~director ~~costs~~fees and ~~facilities~~personnel ~~expenses~~costs. ~~These decreases were partially offset by increased marketing expense.~~

Share-based compensation expense, included in selling, general and administrative expense, was $5855,000 and $2733,000 for the three months ended ~~January~~April 3130, 2026 and 2025, respectively. The increase of $3122,000 is primarily due to the current year vesting of stock options granted to employees, directors and consultants supporting our selling, general and administrative functions.

Research and Development Expense

Research and development expense, primarily consisting of third-party fees and personnel costs, was $7479,000 and $8191,000 for the three months ended ~~January~~April 3130, 2026 and 2025, respectively.

Interest Expense

Interest expense was $~~101~~106,000 and $7078,000 for the three months ended ~~January~~April 3130, 2026 and 2025, respectively. The increase of $3128,000 was primarily due to accrued interest on ~~the~~ convertible notes issued in 2026, 2025, 2024 and 2023.

Other Income

Other income was $82,000 for the three months ended April 30, 2025. During the three months ended April 30, 2025, we received $82,000 from the U.S. Governments Employee Retention Tax Credit Program.

Comparison of the ~~Six~~Nine Months Ended ~~January~~April 3130, 2026 and 2025

Net Product Sales

Net product sales were $1,~~150~~656,000 and $~~946~~1,435,000 for the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025, respectively. ~~The increase of $204,000 was attributable to increased sales across our end user network. Our top customer accounted for $342,000 of net product sales for the six months ended January 31, 2026.~~

~~For~~The ~~the~~increase ~~six~~of ~~months ended January 31~~$221,000 ~~2026,~~was ~~one~~attributable ~~individual~~to ~~customer~~increased ~~accounted~~sales ~~for~~across ~~30% of~~ our ~~net~~end ~~product~~user ~~sales~~network. NoOur ~~other~~top ~~individual~~ customer accounted for ~~10%~~$347,000 ~~or more~~ of ~~our~~ net product sales. ~~All~~for ofthe ~~our~~nine ~~net~~months ~~product~~ended ~~sales~~April ~~were~~30, U2026.~~S. based sales.~~

For the ~~six~~nine months ended ~~January~~April 3130, ~~2025~~2026, ~~two~~one individual ~~customers~~customer accounted for 1821% ~~and 11%~~ of our net product sales. No other individual ~~customer~~ customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

~~During~~For the ~~six~~nine months ended ~~January~~April 3130, ~~2026 and~~ 2025, wetwo ~~recognized~~individual ~~$2,000~~customers accounted for 13% and ~~$1,000~~10% inof ~~royalties~~our ~~from~~net aproduct ~~nonexclusive~~sales. ~~third-party~~No ~~distributor,~~other individual ~~respectively~~customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

During the nine months ended April 30, 2026 and 2025, we recognized $2,000 and $3,000 in royalties from a nonexclusive third-party distributor, respectively.

Cost of Goods Sold

Cost of goods sold was $~~464~~701,000 and $~~395~~603,000 for the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025, respectively. The increase of $6998,000 was primarily ~~was~~attributable ~~due~~ to increased sales during the current fiscal quarter.

Gross margin as a percentage of net product sales, or gross margin percentage, was 6058% and 58% for the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025, respectively. ~~The~~Our ~~slight~~current ~~increase~~year inproduct ~~gross~~mix, ~~margin~~related ~~percentage was primarily attributable~~ to ~~the sale of higher margin packaging configurations of our products during the six months ended January 31~~sales, ~~2026,~~was asrelatively ~~compared~~consistent with the prior ~~period~~year.

Selling, General and Administrative Expense

Selling, general and administrative expense was $12,~~590~~298,000 and $12,~~752~~528,000 for the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025, respectively. The decrease of $~~162~~230,000 was primarily attributable to decreased ~~board fees,~~ personnel costs and ~~facilities~~board ~~expenses~~of director fees. These decreases were ~~partially~~ partially offset by increased ~~marketing~~professional ~~expense~~service fees.

Share-based compensation expense, included in selling, general and administrative expense, was $92147,000 and $84117,000 for the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025, respectively. The increase of $830,000 is primarily due to the current year vesting of stock options granted to employees, directors and consultants supporting our selling, general and administrative functions.

Research and Development Expense

Research and development expense, primarily consisting of third-party fees and personnel costs, was $~~160~~239,000 and $~~152~~243,000 for the ~~six~~nine months ~~ended~~ ~~January~~ended 31April 30, 2026 and 2025, respectively.

Interest Expense

Interest expense was $~~195~~301,000 and $~~132~~210,000 for the ~~six~~nine months ended ~~January~~April 3130, 2026 and 2025, respectively. The increase of $6391,000 was primarily due to accrued interest on the outstanding 2026, 2025, 2024 and 2023 convertible notes.

Other Income

Other income was $8,000 and $79,000 for the nine months ended April 30, 2026 and 2025, respectively. During the nine months ended April 30, 2025, we received $82,000 from the U.S. Governments Employee Retention Tax Credit Program.

Liquidity and Capital Resources

As of ~~January~~April 3130, 2026, we had $~~273~~983,000 in cash and cash equivalents compared with $~~409~~334,000 in cash and cash equivalents as of July 31, 2025. The net ~~decrease~~increase in cash and cash equivalents was attributable to cash ~~used~~received tofrom ~~fund~~financing ~~operations~~activities of $1,973,000, offset by ~~the note payable financings~~cash ~~that~~used ~~occurred~~to ~~during~~fund ~~the~~continuing ~~six~~operations ~~months~~of ~~ended January 31~~$1, ~~2026~~324,000. Additionally, as of ~~January~~April 3130, 2026, we had $3,~~055~~654,000 of current liabilities, ~~including~~ including $~~767~~719,000 in accounts payable, compared with $938,000 of current liabilities, including $784,000 in accounts payable as of July 31, 2025. The net increase in current liabilities was due to the current portion of the note payable due to related parties.

We have a history of recurring losses, and as of ~~January~~April 3130, 2026 we have a stockholder deficiency of $65,~~273~~839,000. During the ~~six~~nine months ended April ~~January 31~~30, 2026, we recorded a net loss of $1,~~249~~873,000 on recorded net revenue of $1,~~152~~658,000. In addition, during the ~~six~~nine months ended April ~~January 31~~30, 2026 we used $~~856~~1,324,000 in operating activities resulting in a cash balance of $~~198~~983,000 as of ~~January~~April 3130, 2026. Our history of of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the ~~recoverability~~ recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern.

Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In addition, the condensed consolidated financial statements included in this Quarterly Report have been prepared and presented on a basis assuming we will continue as a going concern. Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether. Our financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

We believe the following accounting policies and estimates are critical to aid you in understanding and evaluating our reported financial results.

Revenue Recognition

We recognize revenue in accordance with Financial Accounting Standards Board, (“or FASB”), Accounting Standards Codification, (“ASC”), Topic 606, Revenue from Contracts with Customers, (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control^® as a direct food contact processing aid.

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.

Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

~~The~~Our ~~Company’s~~ licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. We ~~The Company records its~~ record royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.

Variable Consideration

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

Share-Based Compensation

We grant equity-based awards under share-based compensation plans or stand-alone contracts. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

Recent Accounting Pronouncements

See Note 4 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

Off Balance Sheet Arrangements

We do not have any off balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act, and as provided in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As required by Rule 13a-15(b) under the Exchange Act, our management conducted an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing evaluation, our Principal Executive Officer and Principal Financial Officer concluded that as of the end of the period covered by this report our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

In connection with the evaluation required by Exchange Act Rule 13a-15(d), our management, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, concluded that there were no changes in our internal controls over financial reporting during the ~~six~~nine months ended ~~January~~April 3130, 2026 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II – Other Information

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of our business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and any adverse result in these or other matters may arise from time to time that could harm our business. We are not currently aware of any such legal proceedings or claims to which we or our wholly owned subsidiary is a party or of which any of our property is subject that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Item 1A. Risk Factors

In evaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q, including the risk factor included below, as well as the risk factors disclosed in Item 1A. to Part I of our Annual Report on Form 10-K for the fiscal year ended July 31, 2025, which we filed with the SEC on October 29, 2025, (or the “Form 10-K”). Other than the risk factor included below, the risks and uncertainties described in “Item 1A — Risk Factors” of our Form 10-K have not materially changed. Any of the risks discussed in this Quarterly Report on Form 10-Q, including the risk factor included below, or any of the risks disclosed in “Item 1A — Risk Factors” of our Form 10-K, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects.

Risks Related to Our Business and Industry

As a result of our historical lack of financial liquidity, we do not currently have sufficient working capital to fund our planned operations and may not be able to continue as a going concern.

We have a history of recurring losses, and as of ~~January~~April 3130, 2026 we have ~~incurred~~ a ~~cumulative~~stockholder ~~net~~deficiency ~~loss~~ of $~~140~~5,~~243~~839,000. During the ~~six~~ nine months ended April ~~January 31~~30, 2026, we recorded a net loss of $1,~~249~~873,000 on recorded net revenue of $1,~~152~~658,000. In addition, during the ~~six~~ nine months ended April ~~January~~30, 312026, ~~206~~ we used $~~856~~1,324,000 in operating activities resulting in a cash balance of $~~198~~983,000 as of ~~January~~April 3130, 2026. As a result, our existing cash resources are not sufficient to meet our anticipated needs over the next twelve months from the date hereof, and we will need to raise additional capital to continue our operations and to implement our business plan, which capital may not be ~~available~~ available on acceptable terms or at all.

Our capital requirements will depend on many factors, including, among others:

	●	the market acceptance of, and demand for, our products;

	●	the timing and costs of executing our sales and marketing strategies;

	●	our ability to successfully complete the in-plant validation trials requested by potential customers and our ability to convert these trials into customer orders for our products;

	●	the costs and time required to obtain the necessary regulatory approvals for our products, including the required USDA approvals:

	●	the extent to which we invest in new testing and product development, including in-plant optimization trials;

	●	the extent to which our customers continue to place product orders as expected and expand their existing use of our products;

	●	the cost and time to satisfy unique customer requirements regarding validation trials or to support the value proposition and benefits of our products;

	●	the timing of vendor payments and the collection of receivables, among other factors affecting our working capital;

	●	our ability to control the timing and amount of our operating expenses, including the costs to attract and retain personnel with the skills required to implement our business plan; and

	●	the costs to file, prosecute and defend our intellectual property rights.

The above factors, along with our history and near term forecast of incurring net losses and negative operating cash flows, raise substantial doubt about our ability to continue as a going concern. If we do not obtain additional capital from external sources, we will not have sufficient working capital to fund our planned operations or be able to continue as a going concern. We cannot assure you that additional financing will be available when needed or that, if available, we can obtain financing on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

~~None.~~Chief Executive Officer Transition

On June 15, 2026, PURE Bioscience, Inc. (the “Company”) announced that Robert Bartlett would be retiring from his role as the Company’s Chief Executive Officer, effective August 1, 2026 (the “Transition Date”). Following the Transition Date, Mr. Bartlett will continue in his role as a member of the Company’s Board of Directors (the “Board”) and will act as an advisor to the next Chief Executive Officer. The Company also announced the promotion of Jeffrey Kitchell from his current role as the Company’s President to the Company’s Chief Executive Officer and the appointment of Mr. Kitchell to the Board, in each case, to be effective the Transition Date. The Board approved the Transition and Mr. Kitchell’s promotion and appointment to the Board on June 11, 2026.

Mr. Kitchell, 55, has served as the Company’s President since November 2025. He also serves as the Company’s Corporate Secretary, a role he has had since 2019. Mr. Kitchell oversees day-to-day operations, supports the Company’s functions, and implements new structures and processes. Prior to serving as the Company’s President, Mr. Kitchell served as the Company’s Vice President of Operations from April 2023 to November 2025. In addition, Mr. Kitchell has held various other roles since joining the Company in 2001. In these various roles, he managed the Company’s legal affairs and helped secure its intellectual property. Before joining the Company, Mr. Kitchell held various leadership roles in companies ranging from small to large. Mr. Kitchell earned a Bachelor’s Degree in Business Administration from the University of Phoenix.

The Company expects to enter into an employment agreement with Mr. Kitchell in connection with his promotion to the position of Chief Executive Officer, and once the terms of such agreement are finalized, the Company will file a Current Report on Form 8-K to report the required information within four business days after such information is determined or becomes available.

Except as set forth above, there are no arrangements or understandings between Mr. Kitchell and any other persons pursuant to which he was named to this position with the Company or appointed as a director. There are no family relationships between Mr. Kitchell and any of the Company’s directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer. Additionally, Mr. Kitchell does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Board Member Resignation

On June 15, 2026, the Company also announced that Bernard Blotner resigned as a member of the Board and any committees of the Board, effective June 11, 2026. The resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

(c) Securities Trading Plans of Directors and Executive Officers

During the quarter ended April 30, 2026, none of our officers or directors, as defined in Rule 16a-1(f), informed us of the adoption or termination of a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, each as defined in Regulation S-K Item 408.

Item 6. Exhibits

The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

3.1	~~Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)~~	Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)
3.1.1	~~Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)~~	Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)
3.1.2	~~Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on May 19, 2021).~~	Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on May 19, 2021).
3.2	~~Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)~~	Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)
3.2.1	Amendment to the Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2.1 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)
4.1		Form of Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on March 27, 2024).
31.1 *	Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
3.2.1		Amendment to the Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2.1 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)
31.2 *	Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.1 *		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 *	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
31.2 *		Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.2 *	Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.1 *		Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101 *	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarterly period ended January 31, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at January 31, 2026 and July 31, 2025; (ii) Condensed Consolidated Statements of Operations for the three and six months ended January 31, 2026 and 2025; (iii) Condensed Consolidated Statements of Stockholders’ equity for the three and six months ended January 31, 2026 and 2025 ;(iv) Condensed Consolidated Statements of Cash Flows for the six months ended January 31, 2026 and 2025; and (v) Notes to Condensed Consolidated Financial Statements.
32.2 *		Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
101.INS *		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH*		Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith.

Signatures

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PURE BIOSCIENCE, INC.
Date: March 16, 2026	By:	/s/ ROBERT F. BARTLETT
Date: June 15, 2026	By:	/s/ ROBERT F. BARTLETT
		Robert F. Bartlett, Chief Executive Officer (Principal Executive Officer)
Date: March 16, 2026	By:	/s/ MARK S. ELLIOTT
Date: June 15, 2026	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott, Vice President, Finance
		(Principal Financial and Accounting Officer)

Filing Compare · PURE BIOSCIENCE, INC.